Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Safety and Efficacy of EMB 001 in Subjects With Moderate-to-Severe Cocaine Use Disorder

NCT04501874 is registered in ClinicalTrials.gov with Embera NeuroTherapeutics, Inc. as lead sponsor.

NCT NCT04501874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04501874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Safety and Efficacy of EMB 001 in Subjects With Moderate-to-Severe Cocaine Use Disorder
Lead sponsor
Embera NeuroTherapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 29, 2020
Completion date
October 15, 2022
Enrollment
82 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cocaine use disorder